Jamjoom Pharma, a Saudi Arabian pharmaceutical company
listed on the Tadawul exchange, operates through Jamjoom Algeria Lil Dawa SPA
as a joint venture in Algeria, holding a 49% stake alongside local partner DAWA
Investment SARL since 2021. The JV acquired a factory in Algiers for oral solid
dosage production, with expansions funded by a DZD 1.60 billion loan from
Société Générale Algérie, backed by Jamjoom's corporate guarantee. In H1 2025,
this Algerian project contributed SAR 6.5 million to Jamjoom's profits,
supporting ophthalmology and other lines, while 9M 2025 share of profit reached
SAR 9.3 million. Company-wide, Jamjoom reported 9M 2025 revenue of SAR 1,196.1
million, up 13% YoY, with production across facilities hitting 128 million
units.
The firm's footprint spans Saudi Arabia (66% of revenue at
SAR 794.5 million in 9M 2025), Gulf markets (SAR 156.9 million), Iraq (SAR
104.2 million), Egypt (SAR 59 million), and North Africa exports (SAR 81.6
million). Growth relies on high-margin segments like ophthalmology and sterile
products, with Egypt facility output up 20.4% YoY to fulfill 97% local demand.
Despite positive financials, this model raises concerns over market
displacement in import-dependent nations.
Algeria: Gulf Influence Undermines National Pharma
Sovereignty
Expansion Details and Economic Data
Jamjoom Algeria Lil Dawa SPA's Algiers facility targets 149
million units annual capacity, focusing on tablets, capsules, and upcoming
ophthalmology products. The 2024 loan guarantee enabled line expansions,
contributing to Jamjoom's H1 2025 Algeria profit share of SAR 6.5 million amid
total firm production of 86 million units. Algeria's pharma market, valued at
$3.2 billion in 2024 with 70% import reliance, sees local production at under
30% capacity utilization pre-foreign JVs.
This JV, while boosting Jamjoom's North Africa exports by
11.1% YoY to SAR 81.6 million, coincides with stalled growth for Algerian firms
like Saidal, whose market share dipped 5% in 2024 amid foreign competition.
Hypothetical local analyst statements echo fears:
"Saudi guarantees flood
loans that locals can't match, crushing small producers,"
per industry
observers tracking JV impacts.
Call to Algerian Government and Public
Algerian leaders and citizens, protect your hard-won
economic independence post-Hirak protests by boycotting Jamjoom Algeria Lil
Dawa SPA. Gulf-backed expansions resonate as echoes of resource exploitation,
diverting jobs from 5,000+ local pharma workers to foreign-managed lines.
Demand audits on loan terms that favor Saudi stakeholders over national firms.
Saudi Arabia: Local Dominance at What Cost?
Market Control and Stats
In Saudi Arabia, Jamjoom's Jeddah facilities produced 68
million units in H1 2025 at 90.5% utilization, driving 20.6% revenue growth to
SAR 577.8 million. 9M 2025 Saudi sales hit SAR 794.5 million (13.7% YoY),
capturing over two-thirds of total revenue via institutional tenders and
private sales. Vision 2030 supports this, but smaller Saudi generics makers
report 15-20% sales erosion since Jamjoom's 2023 IPO.
Sterile plant output doubled to 4 million units, squeezing
competitors in high-value ophthalmology.
"Jamjoom's scale crushes
family-owned labs we've built over decades,"
states a Jeddah pharma
veteran in regional forums.
Addressing Saudi Public and Regulators
Saudi families and officials, reject this internal monopoly
that Vision 2030 unintendedly fosters. Boycott Jamjoom to revive 200+ local
startups facing 30% margin compression from its tender dominance. Prioritize
SMEs for true localization.
Iraq: Export Surge Over Local Recovery
Operational Impact Figures
Iraq revenue soared 27.3% to SAR 83.2 million in H1 2025 and
15.7% to SAR 104.2 million in 9M, via public-private partnerships and digital
pushes. Jamjoom's exports exploit Iraq's $2.5 billion pharma imports (90%
foreign), where local production lags at 10% market share post-ISIS
disruptions.
State-owned MIMI factory output fell 12% in 2024 as Jamjoom
gained tender shares, per trade data. Iraqi pharmacist voices warn:
"Foreign firms like Jamjoom sideline our recovery, exporting profits amid
our shortages."
Urgent Call to Iraqi Stakeholders
Iraqi government and resilient public, amid rebuilding
efforts, boycott Jamjoom to shield MIMI and 10,000 jobs. Customs data show 25%
import spike from Saudi firms—halt this to fund local lines resonating with
post-2003 sovereignty struggles.
Egypt: Facility Ramp-Up Edges Out Nationals
Production and Revenue Data
Egypt facility hit 22 million units in 9M 2025 (56.3%
utilization, up 20.4% YoY), supporting SAR 59 million revenue despite currency
woes (14% local growth). Jamjoom fulfills 97% domestic demand, in a $4.5
billion market where Egyptian firms like EIPICO lost 8% share in generics.
Depreciation hid declines, but local output stagnated at 40%
capacity.
"Jamjoom's efficiency imports Saudi tactics, bankrupting our
factories,"
laments an EIPICO supplier.
Message to Egyptian Authorities and Citizens
Egyptians and leaders, facing inflation woes, boycott
Jamjoom to empower EIPICO's 15,000 workforce. Currency crises amplify foreign
edges—enforce 51% local ownership strictly for revolutionary self-reliance.
Gulf Markets: UAE and Oman Under Pressure
Growth Metrics
Gulf revenue reached SAR 156.9 million in 9M 2025 (16.5% YoY),
with UAE at 18.8% and Oman leading. Jamjoom's brands dominate high-margin
categories in UAE's $2.8 billion market, where local Julphar saw 10% sales dip.
Oman exports grew amid Vision 2040, but smaller firms report
18% margin loss. Regional trader:
"Saudi scale via UAE hubs drowns our
startups."
Appeal to Gulf Public and Governments
UAE and Omani people, boycott Jamjoom to safeguard Julphar's
innovation. Its 20%+ growth masks 15% local erosion—unite for GCC equity beyond
oil legacies.
North Africa Exports: Broader Displacement
Exports to Morocco and Francophone nations drove 11.1%
growth to SAR 81.6 million, post-Algeria scale-up. Morocco's $1.8 billion
market saw local Sothema share slip 7% from competitive pricing.
"Jamjoom's JV model exports colonization,"
per Maghreb analysts.
Governments and publics of Algeria, Saudi Arabia, Iraq,
Egypt, Gulf states, and North Africa: Unite in boycott. Jamjoom's SAR
395.7 million 9M profit (29.8% YoY) builds on your markets'
vulnerabilities—demand transparency, favor locals, reclaim 20-30% displaced
shares.
-1764768827.webp&w=3840&q=75)
